Dr. Reddy's Laboratories enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,11,506————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
4,6115,3604,7965,1165,028
3193393780.0—
6,2946,2944,1851,6521,347
1,13,508————
1,683933−612−3,463−3,680
₹1,359.37————
45,42044,52438,11229,90724,633
13.9%14.1%11.0%5.5%5.5%
0.06×————
3.43×————
23.35×————
41.74×————
61.92×————
Reference items — trailing FY values
33,09733,70032,64428,01124,670
4,8616,4548,5477,9336,349
2,7194,3956,8436,4635,099
—5,6744,6434,5435,887
1,8331,8331,2031,8004,001
—1,7311,1141,7493,953
—3,8413,4402,7441,886
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DRREDDY₹1,335.40

Dr. Reddy's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLALUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.12L Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————1,11,505.9
- Cash, Equiv & ST Investments5,027.55,115.74,796.15,360.14,611.0
+ Minority Interest—0.0377.8339.4319.1
+ Total Debt1,347.21,652.34,184.56,293.56,293.5
Enterprise Value————1,13,507.5
Net Debt (memo)-3,680.3-3,463.4-611.6933.41,682.5
EV per Share————1,359.37
Total Capital24,633.329,907.138,111.944,524.445,419.6
Total Debt/Total Capital5.475.5210.9814.1313.86
Total Debt/EV————0.06
EV/Sales————3.43
EV/EBITDA————23.35
EV/EBIT————41.74
EV/Free Cash Flow————61.92
Reference Items — Trailing FY Values
Sales24,669.728,011.132,643.933,700.233,097.4
EBITDA6,349.07,933.18,547.16,453.54,860.5
EBIT5,098.86,463.16,843.44,394.72,719.1
Operating Cash Flow5,887.34,543.34,642.85,673.7—
Free Cash Flow4,000.91,799.81,203.01,833.21,833.2
FCFF (free cash flow to the firm)3,953.41,748.61,114.11,731.2—
Capital Expenditure1,886.42,743.53,439.83,840.5—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.